BioLineRx Ltd.

2.87+0.0200+0.70%Vol 311.90K1Y Perf 69.99%
Apr 9th, 2021 16:00 DELAYED
BID2.80 ASK2.88
Open2.88 Previous Close2.85
Pre-Market- After-Market2.87
 - -  - -%
Target Price
11.33 
Analyst Rating
Strong Buy 1.00
Potential %
294.77 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★ —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap122.29M 
Earnings Rating
Buy
Price Range Ratio 52W %
51.94 
Earnings Date
19th May 2021

Today's Price Range

2.812.88

52W Range

1.404.23

5 Year PE Ratio Range

-2.90-1.40

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
0.70%
1 Month
0.70%
3 Months
9.54%
6 Months
80.50%
1 Year
69.99%
3 Years
-78.50%
5 Years
-80.27%
10 Years
-

TickerPriceChg.Chg.%
BLRX2.870.02000.70
AAPL132.992.63002.02
GOOG2 285.8820.44000.90
MSFT255.852.60001.03
XOM55.87-0.1300-0.23
WFC40.500.47001.17
JNJ161.25-1.7200-1.06
FB312.46-0.5600-0.18
GE13.600.15001.12
JPM156.281.16000.75
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.25-0.61-144.00
Q03 2020-0.36-0.3016.67
Q02 2020-0.60-0.4525.00
Q01 2020-0.83-0.6027.71
Q04 2019-0.64-0.97-51.56
Q03 2019-0.67-0.4040.30
Q02 2019-0.65-0.0493.85
Q01 2019-0.75-0.750.00
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.1582.14Positive
6/2021 QR-0.1678.95Positive
12/2021 FY-0.65--
12/2022 FY-0.67--
Next Report Date19th May 2021
Estimated EPS Next Report-0.15
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume311.90K
Shares Outstanding42.61M
Trades Count1.21K
Dollar Volume3.36M
Avg. Volume1.86M
Avg. Weekly Volume401.21K
Avg. Monthly Volume395.80K
Avg. Quarterly Volume1.96M

BioLineRx Ltd. (NASDAQ: BLRX) stock closed at 2.87 per share at the end of the most recent trading day (a 0.7% change compared to the prior day closing price) with a volume of 315.58K shares and market capitalization of 122.29M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 38 people. BioLineRx Ltd. CEO is Philip Serlin.

The one-year performance of BioLineRx Ltd. stock is 69.99%, while year-to-date (YTD) performance is 13.89%. BLRX stock has a five-year performance of -80.27%. Its 52-week range is between 1.4 and 4.23, which gives BLRX stock a 52-week price range ratio of 51.94%

BioLineRx Ltd. currently has a PE ratio of -1.20, a price-to-book (PB) ratio of 4.68, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -56.85%, a ROC of -64.43% and a ROE of -102.86%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from BioLineRx Ltd., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.15 for the next earnings report. BioLineRx Ltd.’s next earnings report date is 19th May 2021.

The consensus rating of Wall Street analysts for BioLineRx Ltd. is Strong Buy (1), with a target price of $11.33, which is +294.77% compared to the current price. The earnings rating for BioLineRx Ltd. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

BioLineRx Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

BioLineRx Ltd. has a Neutral technical analysis rating based on Technical Indicators (ADX : 16.61, ATR14 : 0.32, CCI20 : -104.77, Chaikin Money Flow : -0.10, MACD : -0.06, Money Flow Index : 33.81, ROC : -15.41, RSI : 44.82, STOCH (14,3) : 28.45, STOCH RSI : 0.59, UO : 45.92, Williams %R : -71.55), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of BioLineRx Ltd. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

BioLineRx Ltd.

BioLine Rx Ltd is a clinical-stage biopharmaceutical development company with a strategic focus on oncology. Its development and commercialization pipeline consists of two clinical-stage therapeutic candidates - Motixafortide, a novel peptide for the treatment of solid tumors, hematological malignancies and stem cell mobilization, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, it has an off- strategy, a legacy therapeutic product called BL-5010 for the treatment of skin lesions.

CEO: Philip Serlin

Telephone: +972 86429100

Address: 2 HaMa'ayan Street, Modi'in 7177871, , IL

Number of employees: 38

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

55%45%

Bearish Bullish

61%39%

Bearish Bullish

61%39%

News

Stocktwits